Dr. Lucas moved to the University of Florida in 2006_ from the Robarts Research Institute and University of Western Ontario in London,Ontario, Canada, where she has been a principal investigator studying inflammation, specifically monocyte and T lymphocyte activation in vascular disease. Dr. Lucas is also co-inventor and co-founding scientist for Viron Therapeutics, Inc., a biotechnology company that is now in clinical trial analyzing viral anti-inflammatory proteins as a new class of therapeutic agents. Dr. Lucas is a practicing interventional cardiologist in addition to running an active basic research lab in vascular inflammatory research with bovver 100 paper and reviews and 16 patents published. She has been an active member of the Canadian Society for Atherosclerosis and Thrombosis Board having also served as Editor-in-Chief and serves on the American Heart Association grant panel. She is additionally on the editorial board for several journals. Dr. Lucas also directs an annual medical mission to Fte. Liberte in Haiti.
Ion channels, Functional Genomics and Proteomics, Phenomics, Cardiac Electrophysiology and Pharmacology, Cardiac Ischemia, Cardioprotection, Myocardial Hypertrophy and Heart Failure.
1. How many years have you been associated with the current research?
2. What is the research topic you are working on now?
1) Serine proteases: serpin and chemokine: GAG interactions in inflammatory vascular disease,
2) Virus-derived anti-inflammatory proteins as new class of therapeutic –development of serpin and chemokine:GAG modulating reagents,
3) Serpin reactive center peptides as anti-inflammatory reagents, 4) Serpin tretament for cancer and non-coding RNA responses
3. What are attributes for a quality article?
Innovation, a clear progression to a new scientific insight or discovery, hypothesis driven research, rational scientific plan and approach, appropriate research controls, scientific integrity, statistical significance, clarity of
4. Do you have any research funding (NIH or other national funding) now?
Yes NIH and AHA
5. When did you become an editor of OMICS Journal?
6. Where can the journal find the maximum scope in terms of niche?
Areas of previously unreported, new research not yet accepted as dogma, non coding RNA, wound healing, ischemia reperfusion, transplantation rejection and vasculopathy, genetic testing, personalized medicine, heart failure, stem cell research, arrhythmias, inflammation.
7. What is your greatest career accomplishment?
Discovery and development of a new class of virus-derived anti-inflammatory proteins with a first in man successful clinical trial of a viral serpin protein.
8. How does the published scientific content assist the potential researchers?
New approaches, innovative ideas, confirmation of current postulates and ideas
9. What is the purpose of serving as an editor?
1) Evaluate articles for innovation, progession, integrity, 2) invite research articles, 3) assign reviewers for submitted manuscripts, 4) editorials
10. Do you have any patents?
Yes 17 patents
11. Have you contributed any editorials or papers (any types) to OMICS Journals in the past two years?
Yes four editorials and one manuscript–all published in JCEC
12. Do you plan to contribute any editorials or papers to OMICS Journals in the next year?
Yes one editorial is in progress
13. How would you define your experience with OMICS Group?
Supportive but sometimes hard to contact Occasioanlly difficutl to understand due to language barriers but these can be overcome.
14. Your opinion on conducting Editorial Board meetings at related Conferences?
An excellent idea – however these can be done via conference call as well as for other journals
15. Would you recommend OMICS to your friends or colleagues?
Yes I have done so
16. How do you differentiate Journal of Clinical & Experimental Cardiology with other journals in the field?
A medium for publishing research that spans clinical and basic research, a venue for new ideas not yet accepted in mainstream dogma, also an excellent medium for publishing solid research confirming or expanding prior studies